Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Apellis Pharmaceuticals I...

    NASDAQ: APLS · Real-Time Price · USD
    18.32
    -0.51 (-2.71%)
    At close: Jun 16, 2025, 3:59 PM
    18.30
    -0.11%
    After-hours: Jun 16, 2025, 04:04 PM EDT
    -2.71%
    Bid 18.02
    Market Cap 2.3B
    Revenue (ttm) 775.84M
    Net Income (ttm) -223.68M
    EPS (ttm) -1.8
    PE Ratio (ttm) -10.18
    Forward PE -31.05
    Analyst Hold
    Ask 19.31
    Volume 1,306,070
    Avg. Volume (20D) 2,649,447
    Open 18.77
    Previous Close 18.83
    Day's Range 18.00 - 18.77
    52-Week Range 16.10 - 43.15
    Beta 0.67

    About APLS

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol APLS
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for APLS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    2 weeks ago
    +13.05%
    Apellis Pharmaceuticals shares are trading higher ... Unlock content with Pro Subscription
    1 month ago
    -5.91%
    Apellis Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q1 sales results.
    news image

    1 week ago · zacks.com

    Why Is Apellis Pharmaceuticals (APLS) Up 7.2% Since Last Earnings Report?

    Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock?

    news image

    3 weeks ago · seekingalpha.com

    Apellis Pharmaceuticals: Have Some Patience

    Apellis Pharmaceuticals is a Buy due to the significant FCF potential of SYFOVRE® and EMPAVELI®, with SYFOVRE® projected to exceed $1bn in annual sales by 2028. SYFOVRE® has shown efficacy in slowing ...

    news image

    1 month ago · zacks.com

    Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down

    APLS stock falls as it reports weaker-than-expected first-quarter 2025 results, wherein both earnings and revenues miss estimates.

    news image

    1 month ago · fool.com

    Why Apellis Pharmaceuticals Wilted on Wednesday

    A big quarterly earnings miss was the news driving down the value of Apellis Pharmaceuticals (APLS -5.99%) stock in the middle of the trading week. Investors didn't take this development well, and the...

    news image

    1 month ago · seekingalpha.com

    Apellis Pharmaceuticals, Inc. (APLS) Q1 2025 Earnings Call Transcript

    Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q1 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants Tracy Vineis – Vice President-Communications Cedric Francois – Co-Founder and ...

    news image

    1 month ago · zacks.com

    Apellis Pharmaceuticals (APLS) Reports Q1 Earnings: What Key Metrics Have to Say

    The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall...

    news image

    1 month ago · zacks.com

    Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Lags Revenue Estimates

    Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.54 per share a year ago.

    news image

    1 month ago · zacks.com

    Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

    Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    news image

    2 months ago · zacks.com

    APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag

    The FDA accepts Apellis' sNDA seeking label expansion of Empaveli to treat two rare kidney diseases for review under the Priority Review pathway.

    news image

    2 months ago · benzinga.com

    FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals

    The U.S. Food and Drug Administration (FDA) on Tuesday accepted and granted Priority Review designation to Apellis Pharmaceuticals, Inc.'s APLS supplemental New Drug Application (sNDA) for Empaveli (p...

    Add to Watchlist